Especially among 4 patients harbouring EGFR or ALK mutation, 3 patients achieved partial response and 1 stable disease, which is in accordance with the prospective study evaluating the efficacy of EGFR TKI for the treatment of lung cancer patients with poor performance status [13]. This evidence concerns the gene EGFR and lung carcinoma.